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Abstract: Poly- and mononuclear metal complexes of 2,3,11,12-bis[4-(10-aminodecylcarbonyl)]benzo-18-
crown-6 (L) and Cu(II); Ni(II); Co(II) and Cr(III) have been synthesized and characterized by standard
physico-chemical procedures. In the newly prepared complexes the crown moiety oxygen atoms of the
macrocyclic host did not generally interact with metal ions, whereas the two amino groups of the ligand
always did. Several of the newly synthesized compounds act as effective antifungal agents against
Aspergillus and Candida spp., some of them showing activities comparable to ketoconazole, with minimum
inhibitory concentrations in the range of 0.3 -0.5 gg/mL. The mechanism of antifungal action of these
coordination compounds is probably connected to an inhibition of lanosterol-14-o-demethylase, a metallo-
enzyme playing a key role in sterol biosynthesis in fungi, bacteria and eukariotes.
Introduction
Since the discovery of the crown-ether ligands in the late 1960s, these types of molecules have been
recognized as specific complexing agents for alkaline and alkaline-earth metal ions Il[:l as well as for organic
ammonium derivatives such as amines, amino acids, and related compounds (obviously in protonated
state). [31
Two type of complementarities between the metal ion and the crown ether can be distinguished.
Firstly, when a metal ion directly fits into the cavity, interacting equally with all donor atoms present,
spherical molecular recognition has been evidenced, leading thus to stable supramolecular complexes. [41
When the cavity size and the radius of the metal ions are not compatible with each other, out of cavity
coordination or fractional coordination by other available sites has been evidenced in the isolated
supramolecular complexes. [51161 The latter case is observed for many transition metal ions: because of their
small size (non-compatible with the relatively large crown cavity such as that of 18-crown-6) or their
preferences for lower coordination numbers, they generally do not fit into such a macrocyclic cavity. For this
reason only a small number of supramolecular complexes of transition metal ions with crown-ethers have
been reported up to now. [5116] Generally in such complexes, the hydrated metal ions form hydrogen bonded
networks with heteroatoms present in the crown ether moiety, giving polymeric one- or two-dimensional
[51161 derivatives. In such cases, crown-ether molecules are hydrogen bonded through the metal bound water
molecules. [6]
We describe here another approach for obtaining some novel complexes of transition metal ions with
a functionalized macrocyclic crown-ether. According to this approach, the coordination sphere of the metal
ions is completed by secondary coordination sites, chemically grafted on the macrocyclic cavity, which then
participate in the molecular recognition processes together with the macrocycle. In this way the metal ion
macrocyclic receptor interactions become more intense, leading to new specific supramolecular arrays.
We have previously reported some ditopic macrocyclic derivatives containing different moieties in
their second coordination sphere (such as amino, ammonium, pyrilium, pyridinium or L-amino acid groups).
[7][8][9110][11][12] Their complexation properties evidenced new multiple molecular recognition processes of the
metal ions or of certain amino acids, due to the combination of different types of non-covalent interactions.
[9][10] A selective membrane transport of Ag+/Cu
++ by using functionalized dibenzo-18-crown-6 derivatives
chemically grafted in a solid heteropolysiloxane matrix was also evidenced as being due to a synergetic
supramolecular effect. [0][1
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In this paper we report the preparation of new supramolecular complexes of 2,3,11,12-bis[4-(10-
aminodecylcarbonyl)]benzo-18-crown-6, (L), previously reported by us [g][9][10][ll][12] and various metal salts
of the type MCI y H20 (M=Cu(II), y=2; Ni(II),, y=6; Co(II), y=3; Cr(III), y=6). The new complexes were
characterized by analytical and spectroscopic methods that allowed us to propose their structure, since good
crystals for X-ray diffraction experiments could not be obtained.
NH NH
=CI
= H2N
C1
2 3
Results and Discussion
Treatment of bis-amine 1 with different hydrated metal salts (MCIx y H20: M=Cu(II), y=2; Ni(II),
y=6; Co(II), y=3; Cr(III), y=6) led to a new series of supramolecular complexes of transition metal ions 2-9
(see Experimental).
The new supramolecular complexes 2-9 reported here were characterized by elemental analysis, IR
and UV-VIS spectroscopy.
Elemental analysis data for compounds 2-9 were within +0.5% of theoretical values calculated for
the proposed formulae, evidencing different stoichiometries of combinations between the macrocyclic
receptor 1 and the transition metal salts.
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Table l" Selected IR bands of liand and its transition metal complexes 2-9.
Compound Vc.o.csim[Cm"1] VC.O.Ca VC.O_Ca VH20
[cm"] [cmll Icm"l
1059 1136 1261
2 1055 1133 1264
3 1056 1131 1264 3448,3620
4 1056 1131,1148 1264 3405
5 1056 1131,1148 1264 3368
6 1056 1132,1148 1266 3437
7 1055 1125,1149 1263 3554
8 1056 1129,1148 1275 3458
9 1056 1130,1148 1264 3445
In its IR spectrum, the diamine exhibits two weak absorption bands at 3369 and 3438 cm
1
attributable to the free (unassociated amino), antisymmetrical and symmetrical N-H vibrations, respectively,
and at 1423-1456 cm
1 characteristic for the VC-N vibration. The shift with 100-150 cm
1 towards lower wave
numbers of the -NH2 vibrations in the IR spectra of all the complexes reported here is indicative for metal
coordination through the nitrogen atom(s). The VC-N vibration also undergoes a downfield shift with 5-10 cm
in the new complexes as compared to the same vibration in the free ligand. Changes of the ether vibrations
are also observed (table 1) on going from bis-amine 1 to its metal complexes, both for the symmetrical (Vc-o-c
sm) as well as the antisymmetrical (Vc-o-c Vc-o-c A,.) aromatic ether stretchings, probably due to the
participation of ether-oxygen atoms in the coordination process, or due to hydrogen bonding with water
molecules.[3]
OH2 NH2
0
___--__-[ >o
=_2 H2N
OH2
H20
4 5
Stereochemical information for the new complexes 2-9 was obtained from the absorption electronic
spectra of these compounds. Thus, in the electronic spectra of the Cu(II) derivatives CuCI4L 2 and
Cu3CI4L(H2Oh 3 a large band located in the range 10-18 x 103 cm
1 has been evidenced. By deconvoluting it
using the Gauss method, [14] the following transitions bands were observed: at 11.35 x 103, 14.37 x 103, 15.7
x 10 cm for complex 2 and 11.89 x 10, 14.59 x 10, 14.63 x 10" cm for complex 3, respectively,
22 22 22 according to the dz ---d .y, dxy-+dx .y and dz, dyz--)dx .y transitions. (Table 2). A second charge transfer
band located at 18-25 x 103 cm has been evidenced, which overlaps with some characteristic bands of the
free ligand. [14] These spectra are characteristic for copper(II) ions in a (pseudo)-octahedral configuration and
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are consistent with a distorted Oh geometry, the chromophores being of the CuNO3CI2 type for complex 2
and the CuNO3CIz and CuCl402 types for complex 3.
The diffuse reflectance spectra of the Ni(II) complexes NiCIL(HO) 4 and Ni4CI4L(H20)4 5 are
also characteristic for a distorted (pseudo)-octahedral surrounding with the following transition bands: v:
13 11.89 x 10 (A2g--) T2g), v2:14.59 x 10" (Ag-+’Tg(F)), 23.49 x l0 cm- Ag-+ T1g(P))and v3:27.78 x 10
cm
-I (charge transfer band) for complex 4 (the NiNO30’Cl as chromophore) and v: 12.92 x 103 (3A2g-->3T28),
v2:14.79 x 103 (3alg-->3Tlg(F)) v3:23.49 x 103 cm
"l (3Ag-->3Tg(P)) for complex 5, respectively, (Table
2)(the NiNO20’CI and NiCl402 as chromophores).[41[s]
The complexes CoCiL(HOh 6 and CoaCl4L(H20)4 7 probably possess a distorted tetrahedral
eometry of the metal ions, as confirmed by the presence of a large absorption v3 band associated to the
2---)4TI(P) transition, which is resolved in two bands at 15.94 and 16.69 kK (complex 6) and 14.35 and
15.92 kK (complex 7).I61 The v2 transition, overlapping with ligand transition bands, appeared at E < 10 kK
being generally characteristic for tetrahedral Co(ll) complexes (table 2).161 Such spectra, characteristic for the
cobalt(ll) ion in a (pseudo)-tetrahedral geometry (the light-blue color of the compound is characteristic for
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the symmetric C2v surrounding), contain chromophores units of the type CON2C12 for the complex 6 and
CoNOCI2 and CoCI4 type for the complex 7. [15][16]
The diffuse reflectance spectra of the Cr(III) derivatives Cr3CI4L(H20)4 8 and C r3CI4L(H20)12 9
are also characteristic[41 for a distorted (pseudo)-octahedral surrounding with the following transition bands:
v: 13.31 x 103 (4A2g----)2T2g), v: 14.87 x 103 (4Agg---+2E), v3:23.24 x 103 cml(aA2g---)aT2g), 27.28 x 103 cm
4 4 4 4 A9 --
Ytg(F)) and 37 37 Ag- T(P)) for complex 8 (the CrNOCI3 chromophore) and vt" 11 29 x 10 "g -g g
4 (4A2g--’)2T2g), V2:15.12 x 103 (4A2g---)2Eg), v3:22.49 x 103 cml(aA2g--)aT2g), 27.28 x 103 cml(aA2g---- Tlg(F))
and 36.76 (A2g--aT(P)) for complex 5 (Table 2) (CrNO2CIz and CRO2C14 chromophores).
Biochemistry and biological activity ofthe new complexes
Opportunistic fungal infections are an increasingly important cause of morbidity and mortality, with
Aspergillus and Candida species being the most common such pathogens.[7’ 181 Members of the genus
Aspergillus are associated with an impressive spectrum of diseases in humans, ranging from benign
colonization of the lung to severe pathologies such as invasive aspergillosis or allergic bronchopulmonary
aspergillosis,t91 Although A. fumigatus has been identified as the most common etiological agent in the
human diseases, being considered a pathogen and allergen at the same time,[191’ I201 recent data showed the
Table,,2" Electr,onic spectroscopic data for, complexes 2-9.
Complex Absorbtion band (kK) Assigned transition
Cll C|4 L, 2 1.35 (V1) qz""’-’)qx2-y 2" 14.37(v2) OxY-’-)Ox "Y2 7.50(V3) dxz, .dyz----)dx .,-y
Cu3CI4L(H20)2 3 11.89 (v) dz---->dx.v
14.59(v)
2
(lxy"’)Clx -y
14.63 dxz, dyz-->dx2-y
18.549v3) charge tr,ansfer
Ni2CI2L(H20)2, 4 11.89 (Vl) A2g’-Tzg
14.59 (v2) Atg-Tg(F)
23.49 A g--) Tlg(P)
27.78 (v3) chgrge tr.ansfer
Ni4CI4L(H20)4, 5 12.92 (Vl) A2g-s?Tg
14.79 (v2) glg--Tg(F)
23.49 4A lg--.Tg(P)
CoCi2L(H20)2, 6 E<10 (V2) A2-->T(F)
15.94 (v3) 4A2--->4T(P)
16.69
Co3C14L(H20)2 7 E<10 (V2) 4A2-->4T(F)
14.35 (v3) 4A2-")4T! (P)
15.92
CraCI4L(H20)4 8 13.31 (v) 4A2g---)2Tzg
14.87 (v2) 4A2g---)2Eg
23.24 4A2g-’-)4T2g
27.28 4A2g--)4Tlg(F)
37.37 (v3) 4A2,--->4TIg(P)
Cr3CI4L(H20)I 9 11.29 (Vi) 4/2g--’--)2T2g
15.12 (v2) 4A2g--2Eg
22.49 4A2g’-’)’4Tzg
27.28 4Agg---)4Tlg(F)
36.76 (V3) 4gt---)4Y 1,u(P)
apparently benign A. niger and flavus to be involved in life-threatening conditions such as fungal
endocarditisI21 as well as endogenous endophthalmitis, leading in many cases to an irreversible loss of visual
outcome. I221 Moreover, these and other fungi developed resistance to many of the clinically used drugs, such
as ketoconazole 10 or itraconazole 11, so that novel pharmacological agents of this type are permanently
needed. [19-221
The mechanism of action of many fungistatic drugs, such as the widely clinically used azoles mentioned
above, 10 and 11, [23-26] consists in inhibition of a metallo-enzyme, sterol 14-ot-demethylase (CYP51A1),
which is a microsomal cytochrome P-450 dependent protein belonging to a gene superfamily involved in
[97 291 sterol biosynthesis in fungi, plants and animals.- CYP51A1 has been shown to catalyze the conversion of
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lanosterol 12 to the 14-desmethylated derivative, ergosterol 13, through a complicated oxidative sequence
involving 4,4-dimethylcholesta-8,24-dienol and 4,4-dimethyl-cholesta-8,14,24-trienol, as well as the CH2OH,
CHO and COOH derivatives corresponding to the 14-methyl carbon atom of lanosterol, followed by
o
10: Ketoconazole CI
Cl
11: Itraconazole
decarboxylation of the latter compound and release of formic acid.[3321 Inhibition of CYP5 1A1 by azole
antifungals causes thus depletion of ergosterol and accumulation of 14-methylsterols in the membrane of
fungal cells, disturbing the membrane function and causing the death of these organisms.Is’24-31
Taking into account our interest for the design and preparation of novel biologically active
coordination compounds, we have recently reported several classes of antifungals such as aminoglutethimide
derivativesI331, phenoxathiins,
pal phenoxathiin-10,10-dioxides, [351 phenazines,
p61 as well as some of their
metal complexes,
p3’371 Such compounds generally showed a large variety of interesting biological activities,
possessing among others antifungal activity against several fungi such as Aspergilli and Candida. [33"371 Some
of these compounds were shown to interact with the ergosterol synthesis pathway in the sensitive fungi A.
H3C H3CCH3
CH
H __CHa H.
HO- ,"/<’C
v HO
H3C H
12: lanosterol 13: ergosterol
niger,[4’’71 possessing thus a similar mechanism of action with the azole antifungals. It appeared thus of
great interest to test whether the coordination compounds of the crown ether derivative 1, of the type 2-8,
possess antifungal activity. The rationale of looking for the antifungal activity of compounds of the type
reported in the present paper is the following one: substrates of CYP51A1 and related enzymes are generally
bulky molecules (sterols possessing several bulky side chains) which must be oxidized at a specific methyl
group. Thus, their interaction with the active site Fe(III) ion of the prosthetic group of cytochrome P450 is
governed by a multitude of both hydrophobic as well as polar interactions.I71 The same mechanism is valid
for the interaction between CYP51A1 and its inhibitors (such as the azole antifungals). Moreover, many
antifungal compounds (see for instance the structure of itraconazole) possess themselves a bulky and
relatively rigid structure, together with one or more highly polar moieties which are important for their
interaction with the prosthetic group as well as with other active site residues in its vicinity. Thus, our
hypothesis was that compounds of the type 2-8 prepared by us, might possess such structural elements, which
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would confer them the desired biological activity, i.e., antifungal action. Mention should be made that the
crown-ether possesses modest antifungal properties, which were discovered casually by us during a normal
screening program for detecting new lead molecules against the three fungi used in the experiments, i.e., A.
niger, A. flavus and C. albicans (Table 3).
Table 3: Antifungal activity of compounds 1-11 against several organisms. MIC’s have been determined as
described in ref. tnl
Compound MIC (g/mL)
A. flavus C 1150 A. niger C418 Candida albicans C316
75 70 35
2 2 9
3 3 2 10
4 7 8 10
5 12 9 14
6 6 5 9
7 9 6 10
8 8 5 9
9 10 7 13
Ketoconazole 10 1.2 1.8 0.06
Itraconazole 11 0.9 0.2 0.02
Table 4: Levels of ergosterol in A. niger cultures after treatment with different concentrations of the
azole CYP51A1 inhibitor itraconazole 11 and compound 2.
Inhibitor Concentration % Ergosterol*
(tg/mL)
Itraconazole 11 0.01 78 + 5
ltraconazole 11 0.05 41 + 7
Itraconazole 0.10 11 + 4
2 0.01 92 +3
2 0.10 63 + 5
2 0.30 29 + 6
2 0.85 8 + 2
*Mean + standard deviation (n 3); The amount of ergosterol present in the same amount ofwet
cells from the culture grown in the absence of inhibitor is taken as 100%.
From data of Table 3 it can be seen that the ligand 1 possesses modest but net antifungal activity
against the three fungi species used in our experiments, whereas the metal complexes of 1 act as much more
effective antifungals than the parent ligand, with potencies sometimes comparable to ketoconazole against
the Aspergilli, but being much less efficient against Candida as compared to the azole antifungals. The metal
ion present in the coordination compound is an important factor for the biological activity, with Cu(II)
derivatives more active than Co(ll) complexes, which in turn were more active than the Ni(II) and Cr(III)
derivatives. It is also interesting to note that the di- or mononuclear complexes were more active than the
corresponding trinuclear derivatives (compare 2 and 3, or 4 and 5, 6 and 7, 8 and 9). The species most
susceptible to inhibition by these antifungals was A. niger, followed by A. flavus, whereas C. albicans was
the most resistant. In fact, against the first fungus, the Cu(lI) derivative 2 for instance is more effective than
ketoconazole, a widely used drug, being only slightly less effective than itraconazole, one of the most potent
antifungals known up to now. [17,23,24]
In order to test the hypothesis that the compounds reported here act as ergosterol biosynthesis inhibitors,
similarly to the azole antifungals, the amounts of ergosterol present in A. niger cultures after treatment with
different concentrations of new inhibitors (itraconazole 11, a potent CYP51A1 inhibitor[7’23’-41 has also been
included in the study as standard) have been determined by means of a HPLC method (Table 4). t391 These
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data show that at low concentrations of inhibitor, around 80-96 % of ergosterol (as compared to the amount
of sterol formed in cultures in which inhibitors have not been added, and which was considered 100%) is still
synthesized. By increasing the concentrations of inhibitors used in the experiments, the amount of
synthesized ergosterol decreased dose-dependently. A similar effect has been observed for the well-known
CYP51A1 inhibitor itraconazole 11 as well as for the new antifungal compound 2 synthesized in the present
study (the most active inhibitor in the series). These data allow us to propose a similar mechanism of action
for the two classes of antifungal compounds, i.e., the inhibition of lanosterol-14--demethylase, although it is
not improbable that our compounds might interfere with (an)other enzyme(s) involved in the ergosterol
biosynthetic pathway. Thus, we presume that our original hypothesis that bulky coordination compounds of
the type described in the present paper might interfere with the prostethic group of CYP51A1, is correct.
Presently it is difficult to make a hypothesis regarding the precise mode of interaction between the inhibitor
and the CYP51 A1 active site, but we consider the carbonyl oxygen or the amino group of derivatives 1-9 as
the most probable candidates for binding to the Fe(III) ion of this metallo-enzyme. In this way one could also
explain why the metal complexes are much more active as compared to the parent ligand 1: thus, 1 possesses
a much more flexible molecule as compared to the metal complexes 2-9, in which the presence of the metal
ion(s) somehow produces much more rigid structures. Such rigid structures probably fit better and bind
tighter to the active site of CYP51A1 as compared to 1, and in consequence the metal complexes act as better
antifungals.
Materials and Methods
IR spectra: CsBr pellets, 400-4000 cm-
Nicolet 2DXFTIR instrument. -Electronic spectra: MgO as reference,
300-1100 nm, diffuse reflectance Elemental analysis: Carlo Erba Instrument CHNS Elemental Analyser,
Model 1106. Reverse-phase HPLC: Beckman instrument, on a g-Bondapak-C18 column, with acetonitrile as
eluting solvent. 2,3,11,12-bis[4-(10-aminodecylcarbonyl)]benzo-18-crown-6, was prepared by the method
[81 previously reported by us metal salts and solvents from Fluka or E. Merck were used without purification.
Ketoconazole and itraconazole were from Janssen, whereas ergosterol and lanosterol used as standards in the
HPLC measurements were from Sigma.
Synthesis of complexes containing 2,3, I 1,12-bis[4-(lO-aminodecylcarbonyl)]benzo-18-crown-6, I as
macrocyclic ligand: 4 10
.4 tool (0.29 g) of (L) dissolved in 25 ml CHCI3 and and 25 ml of methanolic
solutions containing metal salts (MCI y H20: M=Cu(II), y=2; Ni(II),, y=6; Co.(II), y=3; Cr(III), y=6) were
mixed with stirring, working at molar ratio L M of 1:1 (4 10 tool 6.84 10 g CuCI 2HO, 9.48 10- g
NiCl2 6H_O, 7.36 10
.2 g CoC12 3H20, 1.06 10 g CrCI3 6H20) and 1:2 (8 10
-4 tool: 1.36-10 g CuCl2 2H20,
1.89 10 g NiCb_ 6H20, 1.47 10 g CoC12 3H20, 2.13 10 g CrCI3 6HzO), respectively. The resulting
mixtures were refluxed for 60 rain. on a water bath. The complexes precipitated from these solutions were
filtered, washed with methanol and diethyl ether and dried in vacuum The following coordination compounds
were synthesized and characterized: Cu_CI4L (yellow-green) 2, Cu3CIaL(H_O)_, (brown), 3, Ni_CIzL(H20)2
(yellow) 4, NiaCI4L(H20)4 (yellow) 5, CoCI_L(H20), (light blue) 6, Co3ClaL(H20)4 (light green-blue) 7,
Cr3CI4L(H_O)4 (brown-green), 8, Cr3CI4L(H,O)Iz (brown-green), 9. The yields were in the range of 45-82%
0.26 g of 2 (65%), 0.27 g of 3 (62%), 0.17 g of 4 (45%), 0.24 g of 5 (52%), 0.29 g of 6 (82%), 0.24 g of 7
(55%), 0.25 g of 8 (58%), 0,.25 g of 9 (50%)).
CuzCl4L 2: IR (CsBr)cm"" 951, 1055, 1133, 1264, 1427, 1455, 1514, 1595, 1673, 2853, 2926 3205, 3448.
UV-VIS (MgO), cmx 10.3. 11.35, 14.37, 17.50. Analysis: Cu2CI4L (996) found Cu 12.42, C 5].28, H 6.86,
N 2.47, CI 14.00; requires Cu 12.76, C 50.65, H 6.68, N 2.81, C1 14.24.
Cu3Ci4L(HzO)z 3: IR (CsBr,) cml: 950, 1058, 1134, 1264, 1429, 1460, 1514, 1595, 1674, 2854, 2930, 3205,
3460. UV-VIS (MgO), cm"x 103:11.89, 14.59, 14.63, 18.49. Analysis: C u3CI4L(H20)_ (1096) found Cu
17.58, C 46.48, H 6.57, N 2.47, CI 14.28; requires Cu 17.69, C 46.82, H 6.36, N 2.60, CI 14.16.
NiCIL(HO) 4: IR (CsBr)cm"" 876, 953, 156.13131
1148, 1264, 1337, 1428, 1456, 1514, 1596, 1673,
2854, 2927, 3198, 3405. UV-VIS (MgO), cm 11’.89,14.59, 23.49, 27.78. Analysis: Ni_Cb_L(H_O)_
(949) found Cu 12.35, C 65.53, H 7.42, N 2.94, CI 9.45; requires Ni 12.36, C 65.75, H 7.36, N 2.60, CI
14.16.
Ni4CI4L(HO)4:5: IR (CsBr)cm": 875, 953, 1056, 1131 1148 1264, 1337, 1428, 1456, 1514 115v906,,,,
1673,
2853, 2927, 3368. UV-VIS (MgO), cmlx 103" 12.92, lzi.79, ’3.49. Analysis" Ni4Cl4L(U20)4 found
Ni 19.54, C 43.05, H 6.78, N 2.641CI 12.32; requires Ni 19.97, C 42.91, H 6.34, N 2.38, CI 12.06.
CoCIL(HO)I 6: IR (CsBr) cm 876, 953, 10,56, 1,132, 1148, 1266, 1337, 1359, 1428, 1456, 1514, 1596,
1674, 2854, 2926, 3437. UV-VIS (MgO), cm"x 10: <10.0, 15.94, 16.69. Analysis: CoCl_L(HzO)z (892)
found Co 6.34, C 56.89, H 7.46, N 4.62, CI 8.56; requires Co 6.60, C 56.6, H 7.83, N 4.14, CI 8.14.
Co3CI4L(H:zO)4 7" IR (CsBr)cm" 842, 952, 1055, 1125, 1,149, 1264, 1335, 1360, 1426, 1457, 1513, 1596,
1673, 2854, 2927, 3170, 3554. UV-VIS (MgO), cmx 10: <10.0, 14.35, 15.92. Analysis: Co3CI4L(H20)4
(1117) found Co 11.28, C 49.1, H 7.20, N 0.80, CI 14.12; requires Co 11.52, C 49.3, H 6.90, N 0.81, CI
13.87.
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Cr3CI4L(HzO)4 8: IR (CsBr) cm-: 803, 951, 1056 1129 1148, 1,149,
1275, 1339, 1429, 1464 1517, 1596,
1676, 2854, 2927, 3173. UV-VIS (MgO), cmx 10" 13.31 14.87, 23.24, 27.28, 36.7’6. Analysis"
Cr3CI4L(H20)4 (1096) found Cr 10.64, C 49.56, H 7.85, N 2.60, Cl 10.05; requires Cr 10.30, C 49.98, H 7.39,
N 2.78, CI 10.54.
Cr3CI4L(HzO)z 9" IR (CsBr) cm" 786, 875,952, 1056, 1130, 1149, 1.264, 1340, 1429, 1464, 1516, 1596,
1673, 2853, 2927, 3074, 3132, 3156, 3404. UV-VIS (MgO), cmx 10: 11.29, 15.12, 22.49, 27.28, 36.76.
Analysis: Cr3CIaL(H20)2 (1240) found Cr 12.03, C 38.30, H 7.10, N 1.85, CI 15.98; requires Cr 11.89, C
38.45, H 6.91, N 2.14, CI 16.21.
Assay offungistatic activity ofcompounds 1-11
Fungistatic activity was determined by a modification of the growth method recently reported by us,t33371
utilizing two Aspergillus and one Candida spp. Minimum inhibitory concentrations (MICs) have been
determined by the agar dilution method with Iso-Sensitest agar as described by Kinsman et al.I81 The fungi
were cultivated in agar plates at 37C for 5 days, in the nutrient broth (NB, Diagnostic Pasteur), in the
absence and in the presence of 100 0.01 lag/mL of compounds 1-11. Stock solutions of inhibitors were
obtained in DMSO (100 mg/mL) and dilutions up to 0.01 lag/mL were done with distilled deionized water.
The minimum concentration at which no growth was observed was taken as MIC value (g/mL), and
represents the mean of at least two determinations. Standard deviations were generally around 2 3 % (data
not shown).
Assay ofsterols present in thefungi cultures
A reverse-phase HPLC method adapted from the literature,[39] has been used to determine the amount of
sterols (ergosterol 12 and lanosterol 13) present in the fungi cultures. HPLC was performed with a Beckman
instrument, using a Rheodyne pump and column (reverse phase -Bondapack-C18). The fungi have been
cultivated as mentioned above for 5 days, with or without inhibitors added in the nutrient broth. Culture
media were suspended in a small volume of MOPS buffer (pH 7.4) and the cells centrifuged at 20,000g for
30 min. Cells were weighed (wet paste) and broken by sonication. Sterols present in the homogenate were
then extracted in chloroform, the solvent has been evaporated to a small volume and the extracts applied on a
l.t-Bondapak-C18 column, with acetonitrile as eluting solvent. Authentic ergosterol and lanosterol (from
Sigma) were used as standards. The flow rate was of 3 mL/min. The retention times were: 8.87 min for
ergosterol; and 7.62 min for lanosterol, respectively. Blank assays were done for cultures which were not
treated with inhibitors in order to assess the normal levels of sterols present. The amount of ergosterolpresent
in the same amount ofwet cells from the culture grown in the absence of inhibitor was taken as 100%.
I4gJ
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